-
VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally
•
China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT). The partnership, which leverages the companies’ respective expertise and successful track records in virus vector production, aims to deliver innovative solutions in the…
-
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
•
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group,…
-
Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements
•
Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with Shenzhen Eureka Biotechnology Co., Ltd, a domestic CGT-focused Contract Development and Manufacturing Organization (CDMO) service provider. Combining Expertise for Large-Scale Virus Vector ProductionThe collaboration aims to capitalize on Biosmelt’s GMP grade lentivirus vector suspension production…
-
Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab
•
US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology to jointly establish a cell therapy process development platform laboratory. The collaboration aims to advance innovations in cell therapy, although no financial details were disclosed. About Terumo Blood and Cell TechnologiesTerumo Blood and Cell Technologies…
-
Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development
•
Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with compatriot Chengdu Ucello Biotechnology Co., Ltd. The collaboration aims to develop universal cell therapies by integrating Eureka’s CellSep series cell preparation system and its world-class EuLV-based lentivirus production system based on stable cell lines into…
-
China-Based Firms Form Partnership to Advance Cell and Gene Therapy Ecosystem
•
Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co., Ltd, EurekaBio Technology Co., Ltd, SAFE Pharmaceutical Technology Co., Ltd, and SanQ (Beijing) Biotechnology Co., Ltd—have formed a strategic partnership in the cell and gene therapy (CGT) sector. The collaboration aims to create a comprehensive…
-
Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions
•
Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy industry, has reportedly secured RMB 100 million (USD 14.97 million) in a Series B financing round. The funding, led by Eight Roads Capital and joined by Shenzhen Jiufite Private Equity Investment Management and Juke Investment,…
